GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Acura Pharmaceuticals ACUR · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 4 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2021

Revenue

$1.6m

FY2014FY2021

Net income

−$879,000

FY2014FY2021

Free cash flow

−$742,000

FY2014FY2021

Shareholders' equity

$178,000

FY2014FY2021

Income statement

Fiscal years

FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$1.6m$3.6m$2.7m$410,000$3.0m$4.5m$8.6m$751,000
Gross profit—$3.6m$2.7m$410,000$2.8m$4.0m$7.6m−$4.3m
Research and development$1.5m$1.8m$1.5m$1.8m$3.7m$4.0m$2.6m$4.6m
Operating income−$1.2m−$758,000−$725,000−$3.9m−$5.2m−$6.6m−$4.0m−$12.2m
Net income−$879,000−$1.2m−$3.8m−$3.8m−$5.7m−$7.4m−$5.0m−$13.2m
Diluted earnings per share-0.01-0.06-0.18-184.71-0.27-0.62-0.42-1.47

Balance sheet

At each fiscal year end

FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$860,000$1.7m$2.6m$2.2m$4.6m$8.2m$17.0m$16.0m
Cash and short-term investments————$2.2m$5.2m$13.3m—
Total liabilities$682,000$7.6m$7.3m$5.8m$4.6m$7.0m$9.1m$11.0m
Debt$150,000$6.3m$6.0m$4.2m$2.7m$5.4m$7.8m$9.6m
Shareholders' equity$178,000−$5.9m−$4.7m−$3.6m−$27,000$1.2m$7.9m$5.1m
Shares outstanding65m22m21m0m21m12m12m9m

Cash flow

Fiscal years

FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations−$742,000−$719,000−$618,000−$3.9m−$4.5m−$5.6m−$3.7m−$11.0m
Capital spending—————−$75,000−$214,000−$135,000
Free cash flow−$742,000−$719,000−$618,000−$3.9m−$4.5m−$5.6m−$3.9m−$11.2m

Latest quarters

By quarter end

Dec 2021Sept 2021Jun 2021Mar 2021Dec 2020Sept 2020Jun 2020Mar 2020
Revenue$36,000$270,000$613,000$644,000$718,000$410,000$1.4m$1.1m
Gross profit——$613,000$644,000$718,000$410,000$1.4m$1.1m
Operating income−$237,000−$531,000−$300,000−$146,000−$131,000−$565,000$421,000−$483,000
Net income$29,000−$262,000−$387,000−$259,000−$243,000−$678,000$308,000−$595,000
Diluted earnings per share0.00-0.00-0.01-0.00-0.01-0.030.01-0.03
Total assets$860,000$1.4m$1.9m$1.9m$1.7m$2.2m$2.5m$2.0m
Cash and short-term investments$65,000———————
Debt$167,000$266,000$535,000$6.5m$6.3m$6.2m$6.3m$6.0m
Shareholders' equity$178,000$135,000$382,000−$6.1m−$5.9m−$5.7m−$5.0m−$5.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue56.2%-18.9%-22.7%
Operating income-32.3%-28.6%—
Net income-38.8%-34.7%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-38.4%-80.6%-117.7%—
Net margin-40.7%-118.3%-145.7%—

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return687%99456%-98%-37%130%39%291%-69%-53%-64%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 5-to-1 reverse split · 28 Aug 2015
  • 10-to-1 reverse split · 5 Dec 2007

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.